Vis enkel innførsel

dc.contributor.authorTjensvoll, Anne Boletteen_US
dc.contributor.authorLauvsnes, Maria Bogeen_US
dc.contributor.authorNorheim, Katrine Brækkeen_US
dc.contributor.authorOmdal, Roalden_US
dc.date.accessioned2020-06-18T16:49:15Z
dc.date.available2020-06-18T16:49:15Z
dc.date.issued2019-01-17
dc.PublishedTjensvoll AB, Lauvsnes MB, Norheim KB, Omdal R. Severe headache in primary Sjögren's syndrome treated with intrathecal rituximab. Clinical Case Reports. 2019;7:416–418eng
dc.identifier.issn2050-0904
dc.identifier.urihttps://hdl.handle.net/1956/22718
dc.description.abstractA severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive B cells were involved in headache pathogenesis and were eliminated by this procedure.en_US
dc.language.isoengeng
dc.publisherWileyeng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/eng
dc.subjectB cell depletion in CSFeng
dc.subjectHeadacheeng
dc.subjectPrimary Sjögren’s syndromeeng
dc.subjectSystemic lupus erythematosuseng
dc.titleSevere headache in primary Sjögren's syndrome treated with intrathecal rituximaben_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2019-12-12T11:03:39Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2019 The Author(s)
dc.identifier.doihttps://doi.org/10.1002/ccr3.1987
dc.identifier.cristin1696346
dc.source.journalClinical Case Reports


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY